TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in hsCRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QoR-15F score before surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: QoR-15F score after surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Patients That Experience Grade 2-4 GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in walked meters on six minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Functional Assessment of Cancer Therapy summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Who Achieved Clinical Remission at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Amlodipine concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants of Definite Hepatitis E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Volume transfer constant (Ktrans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Anesthesia in 90% of Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of fat and iron measurement by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average daily pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cycle outcome (pregnancy: yes/no)
Endpoint domain: Mortality/survival
Primary endpoint: Ad libitum food intake (lunch, at 120 minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Umbilical artery Pulsatility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Middle cerebral artery Pulsatility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fetal abdominal circumference growth velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Adverse Events (AEs) and treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Daytime Systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Molecular relapse free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Global Health Related Quality of Life (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Respiratory-specific Health Related Quality of Life (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Haemorrhagic sign - Grade ≥ 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombocytopenia <30 G / L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical signs of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms of psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in feelings of empowerment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients With T790M Mutation Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of T790M Mutation Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in grading of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: concentration of autoreactive t-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Independence with Daily Activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of successful Dural puncture on the first needle insertion attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Follow-up of mothers diagnosed with cancer during pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Follow-up of children antenatally exposed to chemotherapy or radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of any vaccine-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of any adverse event of specific interest
Endpoint domain: Adverse events/effects
Primary endpoint: PET uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of milk produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of serum prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neuropsychiatric Inventory Questionnaire (NPI-Q)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Montreal Cognitive Assessment (HK-MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mild Behavioural Impairment - Checklist
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Detrusor Pressure at Peak Urinary Flow Rate (PdetQmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Unscheduled asthma-related visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects With Serum Bactericidal Assay Antibody Titers ≥ 1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain-related Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oro-cecal Transit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients maintaining independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity to detect cardiac sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity to detect cardiac sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients without a surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Sulindac and sulindac metabolite levels in nipple aspirate fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of moist desquamation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: bone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: surface/curve ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: erosion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: reduction in pain or burning when passing urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of cleft patients with an alveolar cleft of <5 mm at time of the first surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cleft size at initial clinic presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of cleft at pre- and post-operative clinic visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cycles completed during transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scoring system for adenomyosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of 131-I-TM-601
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of 131-I-TM-601 administrations
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of progression and survival at 6 and 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Overall time to progression and death
Endpoint domain: Mortality/survival
Primary endpoint: Urinary protein/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite endpoint of time to first occurrence of doubling of serum creatinine, need for chronic dialysis or renal transplantation, or death
Endpoint domain: Mortality/survival
Primary endpoint: Time to Tumoral Event (TTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness of the HECT-CL treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Possible adverse effect of the HECT-CL treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Ease of use of the HECT-CL treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Change From Baseline in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of Fabry disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post operative Pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of post operative pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Common (>=3%) Non-serious Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With the Presence of Anti-drug Antibody
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in repetitive behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in self-injurious behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in obsessive-compulsive thoughts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Jensen visual analogue scale (VAS)-score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Randomized Subjects With Tympanogram Normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with 4-fold or greater rises in HAI antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in time to exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti Xa activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-specific T-cell response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma Concentration of Certolizumab Pegol (CZP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in daily moving time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily movement intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily time in moderate-to-vigorous-intensity activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of genital HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Difference in immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative short-term outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term oncological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dry Eye disease measured by OSDI questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dry eye disease measured by Corneal Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry eye disease measured by topographic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal bone level changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gastrointestinal microbiota diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in urinary microbiota diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: BiliCare TcB Result Compared to TSB Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of treatment in Chronic hepatitis B patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylation abnormalities of the locus H19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: NOSE score change from baseline to 12 months post op
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pH measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiac death, non-fatal myocardial infarction and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Suspected Adverse Drug Reaction Leading to Treatment Termination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events of Grade 3 or Higher Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Failed to Meet PK Targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of the gesture to reach each target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time changes in urinary tracer excretion (Ca-41 and Sr-84)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of the first relapse
Endpoint domain: Adverse events/effects
Primary endpoint: donor engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade III-IV acute graft-vs-host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of extensive chronic GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Slowing of Fetal Growth by 33% or More
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Developmental milestones
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Target lesion failure at 12-Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of stereotactic radiosurgery
Endpoint domain: Adverse events/effects
Primary endpoint: Fat fraction in the muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Identification of gene mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: P-gp activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCAT5 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of days spent in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Injury duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: plasma glucose value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with abnormal laboratory value
Endpoint domain: Adverse events/effects
Primary endpoint: Diastolic myocardial elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: minimum blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: minimum oxygen saturation of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Insulin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma Leptin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Hip disability and Osteoarthritis Outcome Score (HOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of blood donors with repeatedly reactive Platelia Dengue NS1 Ag test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Deaths within 30 days after emergency laparotomy
Endpoint domain: Mortality/survival
Primary endpoint: cortisol level (stress levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diagnostic usefulness of biopsy cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: New onset, clinically significant arrhythmia or conduction system disease
Endpoint domain: Adverse events/effects
Primary endpoint: Significant prolongation in the corrected QT (QTc) interval
Endpoint domain: Adverse events/effects
Primary endpoint: Significant increase in liver function tests
Endpoint domain: Adverse events/effects
Primary endpoint: Significant increase in serum creatinine not explained by diuretic use
Endpoint domain: Adverse events/effects
Primary endpoint: Significant increase in serum creatine phosphokinase (CPK) levels
Endpoint domain: Adverse events/effects
Primary endpoint: Chemotherapy-related grade 2 to 4 diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Clinical Improvement (CI) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases Screened Positive by CTA's
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS monitoring during maintenance of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease control rate at 24 weeks after randomisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Assessment of Change Over Time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in biochemical endpoints (Procollagen I and III, MMPs, cytokines)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of hypertrophic scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Denervation of Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reinnervation of Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative day 0 Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing severe sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Level of influenza viral load (AUC0 d5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and toxicity profile: Unacceptable Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration-time curve from the time of dosing to 72 hours (AUC72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from the time of dosing extrapolated to time infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Faces Pain Scale-Revised (FPS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in CDIP-58 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Concentrations of Amino Acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pressure-induced vasoconstriction of human uterine myometrial arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical Benefit Response (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Self-selected Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical and parasitological cure rate (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Who Are Progression-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes